Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data

Both pembrolizumab (P) and combination of pembrolizumab with platinum-based chemotherapy (PCT) represent standard 1(st)-line options for advanced non-small cell lung cancer (aNSCLC) with PD-L1 tumor proportion score (TPS) ≥50%. The two strategies have never been compared in a randomized trial. 256 c...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncoimmunology
Main Authors: Dudnik, Elizabeth, Moskovitz, Mor, Rottenberg, Yakir, Lobachov, Anastasiya, Mandelboim, Rinat, Shochat, Tzippy, Urban, Damien, Wollner, Mira, Nechushtan, Hovav, Rotem, Ofer, Zer, Alona, Daher, Sameh, Bar, Jair
Formato: Artigo
Idioma:Inglês
Publicado: Taylor & Francis 2021
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7849771/
https://ncbi.nlm.nih.gov/pubmed/33552685
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2020.1865653
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares